Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up

Muscle Nerve. 2012 Jun;45(6):796-802. doi: 10.1002/mus.23272.


Introduction: Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion.

Methods: We performed a long-term study of alternate-day corticosteroids in five 2- to 4-year-old DMD patients. The primary outcome measure was prolongation of the ability to walk.

Results: One patient lost ambulation at age 10. Four patients, aged 16 to 18 were fully ambulant, and 3 of them could still climb stairs. Respiratory function was moderately reduced in 2. Left ventricular ejection fraction was > 45%. Short stature and delayed puberty were the most relevant side effects. Although the negative impact of corticosteroid treatment on growth rate remained their major concern, parents and patients stated that they preferred corticosteroid therapy.

Conclusions: Long-term corticosteroid treatment is effective in prolonging function but not in recovering lost function, and its early use seems appropriate.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / adverse effects*
  • Adrenal Cortex Hormones / pharmacology
  • Adrenal Cortex Hormones / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Longitudinal Studies
  • Male
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Muscular Dystrophy, Duchenne / physiopathology*
  • Prednisone / adverse effects
  • Prednisone / pharmacology
  • Prednisone / therapeutic use
  • Pregnenediones / adverse effects
  • Pregnenediones / pharmacology
  • Pregnenediones / therapeutic use
  • Prospective Studies
  • Puberty, Delayed / chemically induced
  • Stroke Volume / drug effects
  • Stroke Volume / physiology
  • Treatment Outcome
  • Walking / physiology


  • Adrenal Cortex Hormones
  • Pregnenediones
  • deflazacort
  • Prednisone